TY - JOUR
T1 - Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer
T2 - A Hellenic Cooperative Oncology Group study
AU - Nikitas, Nikitas
AU - Karadimou, Alexandra
AU - Tsitoura, Eliza
AU - Soupos, Nikolaos
AU - Tsiatas, Marinos
AU - Karavasilis, Vasilios
AU - Pectasides, Dimitrios
AU - Pavlidis, Nikolaos
AU - Chrisofos, Michael
AU - Adamakis, Ioannis
AU - Murray, Samuel
AU - Fountzilas, Georgios
AU - Dimopoulos, Meleios Athanasios
AU - Bamias, Aristotle
PY - 2012/11
Y1 - 2012/11
N2 - Aim: The association between two polymorphisms of ERCC1 and treatment outcomes after platinum-based chemotherapy in patients with advanced urothelial cancer (UC) was examined. Materials & methods: Genotyping of 19007C>T and 8092C>A polymorphisms was determined by PCR amplification and RFLP in 113 advanced UC patients, treated with platinum-based chemotherapy. Results: Seventy eight patients (69%) were carriers of the 19007T polymorphic allele: 51 (45%) heterozygotes and 27 (24%) homozygotes. Fifty three (47%) patients were carriers of the 8092A polymorphic allele: the frequencies of C/A and A/A genotypes were 37% and 10%, respectively. The T/T genotype was independently associated with prolonged median cancer-specific survival (not-reached vs 14.8 months; p = 0.026). There was no interaction between T/T or any other genotype with the type of platinum derivative (cisplatin/carboplatin). Conclusion: 19007C>T, especially in its homozygotic state, but not 8092C>A polymorphism, could be a useful prognostic marker in advanced UC treated with platinum-based chemotherapy. Original submitted 17 July 2012; Revision submitted 21 September 201.
AB - Aim: The association between two polymorphisms of ERCC1 and treatment outcomes after platinum-based chemotherapy in patients with advanced urothelial cancer (UC) was examined. Materials & methods: Genotyping of 19007C>T and 8092C>A polymorphisms was determined by PCR amplification and RFLP in 113 advanced UC patients, treated with platinum-based chemotherapy. Results: Seventy eight patients (69%) were carriers of the 19007T polymorphic allele: 51 (45%) heterozygotes and 27 (24%) homozygotes. Fifty three (47%) patients were carriers of the 8092A polymorphic allele: the frequencies of C/A and A/A genotypes were 37% and 10%, respectively. The T/T genotype was independently associated with prolonged median cancer-specific survival (not-reached vs 14.8 months; p = 0.026). There was no interaction between T/T or any other genotype with the type of platinum derivative (cisplatin/carboplatin). Conclusion: 19007C>T, especially in its homozygotic state, but not 8092C>A polymorphism, could be a useful prognostic marker in advanced UC treated with platinum-based chemotherapy. Original submitted 17 July 2012; Revision submitted 21 September 201.
KW - cisplatin
KW - human ERCC1 gene
KW - nucleotide excision repair
KW - single-nucleotide polymorphism
KW - urothelial cancer
UR - http://www.scopus.com/inward/record.url?scp=84869022939&partnerID=8YFLogxK
U2 - 10.2217/pgs.12.162
DO - 10.2217/pgs.12.162
M3 - Article
C2 - 23148636
AN - SCOPUS:84869022939
SN - 1462-2416
VL - 13
SP - 1595
EP - 1607
JO - Pharmacogenomics
JF - Pharmacogenomics
IS - 14
ER -
